Tempus Wealth Planning LLC Acquires New Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Tempus Wealth Planning LLC bought a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund bought 5,538 shares of the biopharmaceutical company’s stock, valued at approximately $265,000.

Other hedge funds have also added to or reduced their stakes in the company. abrdn plc bought a new stake in shares of Halozyme Therapeutics in the fourth quarter worth $6,152,000. Alliance Wealth Advisors LLC UT lifted its holdings in Halozyme Therapeutics by 2.9% in the fourth quarter. Alliance Wealth Advisors LLC UT now owns 20,463 shares of the biopharmaceutical company’s stock valued at $978,000 after acquiring an additional 570 shares during the period. Hodges Capital Management Inc. boosted its position in Halozyme Therapeutics by 3.9% in the fourth quarter. Hodges Capital Management Inc. now owns 332,954 shares of the biopharmaceutical company’s stock worth $15,919,000 after purchasing an additional 12,410 shares during the last quarter. Boston Trust Walden Corp grew its stake in shares of Halozyme Therapeutics by 28.0% during the 4th quarter. Boston Trust Walden Corp now owns 874,081 shares of the biopharmaceutical company’s stock valued at $41,790,000 after purchasing an additional 191,465 shares during the period. Finally, Jennison Associates LLC purchased a new stake in shares of Halozyme Therapeutics during the 4th quarter valued at about $731,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on HALO shares. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Piper Sandler lifted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. HC Wainwright restated a “buy” rating and issued a $70.00 price objective on shares of Halozyme Therapeutics in a research note on Tuesday. Wells Fargo & Company lowered their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Finally, JMP Securities upped their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $60.89.

Halozyme Therapeutics Stock Up 0.9 %

NASDAQ HALO opened at $56.77 on Wednesday. Halozyme Therapeutics, Inc. has a 12 month low of $33.15 and a 12 month high of $65.53. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. The stock has a market cap of $7.22 billion, a PE ratio of 18.80, a P/E/G ratio of 0.43 and a beta of 1.25. The stock’s 50 day moving average is $51.00 and its 200 day moving average is $54.35.

Insider Transactions at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the sale, the director now directly owns 38,611 shares in the company, valued at approximately $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.70% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.